Matches in SemOpenAlex for { <https://semopenalex.org/work/W4280510570> ?p ?o ?g. }
- W4280510570 endingPage "2174" @default.
- W4280510570 startingPage "2174" @default.
- W4280510570 abstract "Over the last few decades, an increasing amount of information has been accumulated on biomarkers in non-small cell lung cancer (NSCLC). Despite these advances, most biomarkers have been identified in the adenocarcinoma histological subtype (AC). However, the application of molecular-targeted therapies in the prognosis and treatment of SCC in the clinical setting is very limited, becoming one of the main focus areas in research. Here, we prospectively analyzed the frequency of numerical/structural abnormalities of chromosomes 5, 7, 8, 9, 13 and 22 with FISH in 48 pulmonary SCC patients. From a total of 12 probes, only abnormalities of the 7p12 and 22q12 chromosomal regions were identified as unique genetic variables associated with the prognosis of the disease. The study for these two chromosomal regions was extended to 108 patients with SCC. Overall, chromosome losses were observed more frequently than chromosome gains, i.e., 61% versus 19% of all the chromosome abnormalities detected. The highest levels of genetic amplification were detected for the 5p15.2, 7p12, 8q24 and 22q11 chromosome bands, of which several genes are potentially involved in the pathogenesis of SCC, among others, include the EGFR gene at chromosome 7p12. Patients who displayed EGFR amplification (n = 13; 12%) were mostly older than 65 years (p = 0.07) and exclusively patients in early T-primary tumor stage (pT1−pT2; p = 0.03) with a significantly shortened overall survival (OS) (p ≤ 0.001). Regarding prognosis, the clinical, biological, and histopathologic characteristics of the disease that displayed a significant adverse influence on OS in the univariate analysis included patients older than 65 years (p = 0.02), the presence of lymph node involvement (p = 0.005), metastasis (p = 0.01) and, visceral pleural invasion (VPI) at diagnosis (p = 0.04). EGFR amplification also conferred an adverse impact on patient OS in the whole series (p = 0.02) and especially in patients in early stages (pT1−pT2; p = 0.01). A multivariate analysis of the prognostic factors for OS showed that the most informative combination of independent variables to predict an adverse outcome was the presence of VPI and/or EGFR amplification (p < 0.001). Based on these two variables, a scoring system was built to stratify patients into low- (no adverse features: score 0; n = 69), intermediate- (one adverse feature: score 1; n = 29) and high-risk (two adverse features: score 2; n = 5) groups, with significantly different (p = 0.001) OS rates at 50 months, which were as following: 32%, 28% and 0%, respectively. In the present study, we show that the presence of a high level of 7p12 (EGFR) amplification, exclusively detected in early stage SCC (pT1−pT2), is an independent adverse prognostic factor for OS. The identification of the EGFR gene copy number using FISH techniques may provide a more accurate diagnosis of high-risk populations after the complete resection of the primary tumor. When combined with VPI, three groups of pulmonary SCC were clearly identified that show the extent of the disease. This is of such importance that further prospective studies are necessary in larger series of SCC patients to be classified at the time of diagnosis. This could be achieved with the combined assessment of 7p12 amplification and VPI in primary tumor samples." @default.
- W4280510570 created "2022-05-22" @default.
- W4280510570 creator A5027538650 @default.
- W4280510570 creator A5056236862 @default.
- W4280510570 creator A5084021229 @default.
- W4280510570 creator A5088898789 @default.
- W4280510570 creator A5090056802 @default.
- W4280510570 date "2022-04-27" @default.
- W4280510570 modified "2023-10-16" @default.
- W4280510570 title "Prognostic Impact of EGFR Amplification and Visceral Pleural Invasion in Early Stage Pulmonary Squamous Cell Carcinomas Patients after Surgical Resection of Primary Tumor" @default.
- W4280510570 cites W1490708659 @default.
- W4280510570 cites W1491517465 @default.
- W4280510570 cites W1858316002 @default.
- W4280510570 cites W1953677527 @default.
- W4280510570 cites W1979840121 @default.
- W4280510570 cites W1988442083 @default.
- W4280510570 cites W2005312471 @default.
- W4280510570 cites W2018922262 @default.
- W4280510570 cites W2022384403 @default.
- W4280510570 cites W2037891309 @default.
- W4280510570 cites W2039879950 @default.
- W4280510570 cites W2044805007 @default.
- W4280510570 cites W2074907434 @default.
- W4280510570 cites W2076789869 @default.
- W4280510570 cites W2091258013 @default.
- W4280510570 cites W2092152677 @default.
- W4280510570 cites W2096702281 @default.
- W4280510570 cites W2102792851 @default.
- W4280510570 cites W2105026490 @default.
- W4280510570 cites W2105834225 @default.
- W4280510570 cites W2107304950 @default.
- W4280510570 cites W2112174226 @default.
- W4280510570 cites W2136950355 @default.
- W4280510570 cites W2138604360 @default.
- W4280510570 cites W2144538524 @default.
- W4280510570 cites W2150548739 @default.
- W4280510570 cites W2275877493 @default.
- W4280510570 cites W2307146056 @default.
- W4280510570 cites W2334778962 @default.
- W4280510570 cites W2354317315 @default.
- W4280510570 cites W2417696062 @default.
- W4280510570 cites W2523467126 @default.
- W4280510570 cites W2611714880 @default.
- W4280510570 cites W27388708 @default.
- W4280510570 cites W2751913252 @default.
- W4280510570 cites W2803375876 @default.
- W4280510570 cites W2898003033 @default.
- W4280510570 cites W2914350247 @default.
- W4280510570 cites W2924313489 @default.
- W4280510570 cites W2943883469 @default.
- W4280510570 cites W2947151363 @default.
- W4280510570 cites W2978862704 @default.
- W4280510570 cites W3007300325 @default.
- W4280510570 cites W3092855556 @default.
- W4280510570 cites W3105325180 @default.
- W4280510570 cites W3110833960 @default.
- W4280510570 cites W3113022089 @default.
- W4280510570 cites W3202097074 @default.
- W4280510570 cites W3205352786 @default.
- W4280510570 cites W3217485783 @default.
- W4280510570 cites W4205876263 @default.
- W4280510570 doi "https://doi.org/10.3390/cancers14092174" @default.
- W4280510570 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35565304" @default.
- W4280510570 hasPublicationYear "2022" @default.
- W4280510570 type Work @default.
- W4280510570 citedByCount "1" @default.
- W4280510570 countsByYear W42805105702023 @default.
- W4280510570 crossrefType "journal-article" @default.
- W4280510570 hasAuthorship W4280510570A5027538650 @default.
- W4280510570 hasAuthorship W4280510570A5056236862 @default.
- W4280510570 hasAuthorship W4280510570A5084021229 @default.
- W4280510570 hasAuthorship W4280510570A5088898789 @default.
- W4280510570 hasAuthorship W4280510570A5090056802 @default.
- W4280510570 hasBestOaLocation W42805105701 @default.
- W4280510570 hasConcept C104317684 @default.
- W4280510570 hasConcept C121608353 @default.
- W4280510570 hasConcept C126322002 @default.
- W4280510570 hasConcept C142724271 @default.
- W4280510570 hasConcept C143998085 @default.
- W4280510570 hasConcept C146357865 @default.
- W4280510570 hasConcept C151730666 @default.
- W4280510570 hasConcept C2776256026 @default.
- W4280510570 hasConcept C2777714996 @default.
- W4280510570 hasConcept C2779013556 @default.
- W4280510570 hasConcept C2779134260 @default.
- W4280510570 hasConcept C2780283643 @default.
- W4280510570 hasConcept C2781182431 @default.
- W4280510570 hasConcept C30481170 @default.
- W4280510570 hasConcept C502942594 @default.
- W4280510570 hasConcept C54355233 @default.
- W4280510570 hasConcept C71924100 @default.
- W4280510570 hasConcept C7602840 @default.
- W4280510570 hasConcept C86803240 @default.
- W4280510570 hasConceptScore W4280510570C104317684 @default.
- W4280510570 hasConceptScore W4280510570C121608353 @default.
- W4280510570 hasConceptScore W4280510570C126322002 @default.
- W4280510570 hasConceptScore W4280510570C142724271 @default.
- W4280510570 hasConceptScore W4280510570C143998085 @default.